作者
Roberta A Ballard, William E Truog, Avital Cnaan, Richard J Martin, Philip L Ballard, Jeffrey D Merrill, Michele C Walsh, David J Durand, Dennis E Mayock, Eric C Eichenwald, Donald R Null, Mark L Hudak, Asha R Puri, Sergio G Golombek, Sherry E Courtney, Dan L Stewart, Stephen E Welty, Roderic H Phibbs, Anna Maria Hibbs, Xianqun Luan, Sandra R Wadlinger, Jeanette M Asselin, Christine E Coburn
发表日期
2006/7/27
期刊
New England Journal of Medicine
卷号
355
期号
4
页码范围
343-353
出版商
Massachusetts Medical Society
简介
Background
Bronchopulmonary dysplasia in premature infants is associated with prolonged hospitalization, as well as abnormal pulmonary and neurodevelopmental outcome. In animal models, inhaled nitric oxide improves both gas exchange and lung structural development, but the use of this therapy in infants at risk for bronchopulmonary dysplasia is controversial.
Methods
We conducted a randomized, stratified, double-blind, placebo-controlled trial of inhaled nitric oxide at 21 centers involving infants with a birth weight of 1250 g or less who required ventilatory support between 7 and 21 days of age. Treated infants received decreasing concentrations of nitric oxide, beginning at 20 ppm, for a minimum of 24 days. The primary outcome was survival without bronchopulmonary dysplasia at 36 weeks of postmenstrual age.
Results
Among 294 infants receiving nitric oxide and 288 receiving placebo birth weight …
引用总数
学术搜索中的文章
RA Ballard, WE Truog, A Cnaan, RJ Martin, PL Ballard… - New England Journal of Medicine, 2006
